Skip to main content

Table 1 Patient characteristics

From: Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma

 

Multiple myeloma patients

N = 239

Age (year)

 

   Median (range)

66 (36-89)

Sex, no. (%)

 

   Male

128 (54)

   Female

111 (46)

Phase of disease, no. (%)

 

   Newly diagnosed

87 (36)

   Stable disease

80 (34)

   Relapse/progression

69 (29)

Multiple myeloma treatment during the study, no (%)

 

   No treatment

86 (36)

   MP +/- Thalidomide

55 (23)

   ASCT, newly diagnosed

33 (14)

   ASCT, relapse

8 (3)

   Velcade

7 (3)

   Thalidomide

32 (13)

   Other

15 (6)

   Unknown

3 (1)

  1. MP: Melphalan and Prednisone
  2. ASCT: Autologous stem cell transplantation